Last updated: July 14, 2026
Grifulvin V is a legacy oral antifungal brand built on griseofulvin (a systemic fungistatic agent). For investment decisions, the key fundamentals are (1) long-run erosion of brand economics driven by generic availability, (2) patent and regulatory posture that is typically thin beyond historic composition and use coverage, and (3) limited pipeline adjacency because griseofulvin is a mature, off-patent platform. The highest-impact diligence focus is the exact FDA label and Orange Book status for the “Grifulvin V” listed product, then mapping to any remaining method-of-use, dosing regimen, or formulation patents and to any ongoing Hatch-Waxman litigation that could delay generic entry.
Because “Grifulvin V” is a branded manifestation of griseofulvin, the investment profile is dominated by supply-side pricing dynamics, substitution rates, and whether any branded-specific exclusivities or product-specific IP still bind competitors in the relevant dosage form/strength.
What are the core investment drivers for Grifulvin V (griseofulvin) in the US market?
Grifulvin V fundamentals are usually less about near-term clinical upside and more about durability of branded share and gross-to-net discipline under generic competition.
Demand and use
- Indication set is generally confined to dermatophyte (tinea) infections requiring systemic therapy when topical therapy is insufficient.
- Patient mix and prescribing depend on formulary status, guideline adherence, pediatric and dermatology practice patterns, and payer policies favoring generics.
Supply and pricing
- Griseofulvin’s generic availability is structurally high, which pressures net pricing.
- Brand economics are driven by:
- branded-to-generic substitution rates
- wholesaler buying behavior and rebate structures
- state Medicaid and contract pharmacy formularies
Switching and access
- If a brand-specific formulation change exists (bioavailability, palatability, dosing convenience), that can temporarily stabilize share, but the mechanism must be tied to protectable product characteristics and still surviving IP.
Pipeline and competitive set
- Competitive pressure comes from other systemic antifungals (e.g., terbinafine, azoles, itraconazole) whose prescribing is influenced by dermatophyte species, infection site, and tolerability.
- Investment risk is that systemic prescribing shifts further toward newer agents even when a brand is still present.
What patents protect Grifulvin V (griseofulvin) and how many are likely still enforceable?
Grifulvin V as a product line is exposed to the same patent regime as griseofulvin’s historical IP. In practice, for legacy molecules:
- composition-of-matter protection has long since expired or is near expiry
- remaining IP, if any, tends to be product-specific (formulation, particle size, polymorphs, manufacturing process) or method-of-use (specific dosing regimens or treatment algorithms)
- exclusivity for new formulations is possible but typically limited if the molecule is old and the relevant submission is not recent
Patent estate mapping framework for Grifulvin V
A complete IP map requires Orange Book “Patent Information” fields for the specific FDA application tied to Grifulvin V and then cross-referencing:
- listed patents by type: composition, method of use, formulation, manufacturing
- listed claims to the Grifulvin V label and dosage form/strength
- the assignees to identify likely challengers and licensees
Actionable diligence checkpoint
- Determine whether Grifulvin V has an active Orange Book listing on the specific NDA/BLA that corresponds to the brand.
- If no listed patents remain active for that application, the investment case shifts from IP-based defensibility to commercial execution.
When does Grifulvin V lose exclusivity, and what do generic entry risks look like?
For older antifungals, the generic entry risk is typically realized early due to expiration of molecule-level patents. The remaining question is whether product-specific exclusivities or later-listed formulation/method-of-use patents create a delayed launch window for generics.
Generic launch scenarios
- Full off-patent, no blocking Orange Book patents
- generic entry is already cleared on patent grounds
- the investment risk is ongoing price compression and share drift
- Orange Book patents exist but are weak or design-aroundable
- generics may launch at risk (Paragraph IV) with potential litigation delay
- Orange Book patents exist with strong blocking claims
- delayed generic entry may support longer brand pricing power, but only if the patents are still enforceable for the specific dosage form/strength
Best-case vs base-case
- Base-case for griseofulvin brands is sustained generic substitution and periodic wholesalers’ push toward lower net-cost SKUs.
- Best-case requires surviving product-specific IP or exclusivity that maps directly to the labeled dosing and the product’s formulation.
What is the Orange Book status of Grifulvin V, and which patents are listed?
The Orange Book status is the determinative screen for enforceable FDA-listed IP. For an investment-grade IP view, the Orange Book listing must be tied to:
- drug product NDA number and label
- dosage form and strength covered by the listing
- listed patent expiration dates and patent types
- whether patents are set for terminal disclaimer alignment
Investment implication
- If the Orange Book lists no currently enforceable patents for the Grifulvin V NDA, the brand is economically exposed to generic pricing forces.
- If patents are listed with later expiration, the valuation needs sensitivity to possible Paragraph IV challenges and litigation timelines.
What formulation patents might protect Grifulvin V (dosage forms, strengths, bioavailability)?
For griseofulvin, formulation protection (where present) typically focuses on:
- particle size and solid-state form impacting dissolution
- manufacturing controls affecting bioavailability
- excipient system and tablet profile supporting consistent absorption
- process patents covering granulation, drying, milling, or coating steps
How to diligence formulation defensibility
- Identify whether any listed formulation patents are tied to a specific strength or dosage form.
- Check whether generic labels are allowed via “sameness” determinations or whether they depend on a carve-out or bioequivalence that still must overcome patent claims.
Investment implication
- Formulation patents can extend brand value if they create a practical barrier to generic equivalence.
- If generic manufacturers can launch with equivalent or design-around formulations, the patent impact is likely to be temporary.
Are there method-of-use or dosing regimen patents for griseofulvin that could block generics?
Method-of-use patents, where present, often target:
- specific dosing schedules
- pediatric dosing algorithms
- treatment duration tied to organism, body site, or clinical response
- stepwise regimens (e.g., lead-in therapy then systemic continuation)
Investment implications
- Method-of-use protection can deter “label carve-in” generic strategies if the generic’s intended use is constrained by the patentee’s claims.
- Many generics can still launch by omitting protected uses or changing label language, depending on claim scope and FDA labeling practices. The economic effect is therefore mixed.
What Paragraph IV challenges and patent litigation affect Grifulvin V?
The most decision-relevant litigation items are:
- Paragraph IV certifications against Grifulvin V’s Orange Book patents
- district court cases involving Hatch-Waxman infringement
- Federal Circuit outcomes affecting claim scope and enforceability
- any settlement agreements that define “design-around” or “launch-at” dates
Investment lens
- Active Paragraph IV litigation can create a short-to-mid-term brand protection window.
- Litigation that ends in a settlement with agreed entry dates supports forecasted branded pricing.
- Litigation losses force rapid generic share erosion.
What FDA regulatory milestones matter for Grifulvin V investors?
The FDA milestones that affect investment are:
- latest NDA labeling changes that could shift patent relevance (label carve-in/out changes can matter for method-of-use)
- changes to manufacturing site or SUPAC-related updates that can trigger patent or bioequivalence questions
- any approvals of new strengths or formulations that could create new IP listings
Investment implication
- If Grifulvin V has had recent labeling changes tied to dosing or indications, the method-of-use patent set may be impacted.
- If no meaningful changes exist, the brand’s regulatory trajectory is likely stable and dominated by competitive substitution.
How does Grifulvin V compare with other systemic antifungals on the commercial and IP axis?
From an investment fundamentals perspective, compare griseofulvin against alternatives on three axes:
- Clinical positioning
- terbinafine is often preferred for dermatophyte infections depending on species and site
- oral azoles and other systemic agents compete for overlapping indications
- Cost and formulary
- generics of alternatives also pressure net pricing across the class
- IP reality
- legacy oral antifungals with generics tend to have similar commercial fragility, so the deciding factor is brand execution and remaining defensibility
Investment implication
- Even if griseofulvin remains clinically acceptable, competitors can displace prescribing by formulary preference and treatment guidelines.
- That means the brand value is mostly tied to reimbursement and physician familiarity rather than patent-based growth.
Which companies are likely positioned to challenge Grifulvin V or capture generic share?
In a mature antifungal market, challengers are typically:
- large generic manufacturers with Paragraph IV track records
- domestic and international generic entrants with established griseofulvin supply chains
- authorized generics where contracts exist
Investment diligence
- Use the Orange Book to identify the generic application history, then correlate patent challenges by filing patterns and settlement practices.
- Map to historical generic market share capture and pricing behavior.
What is the revenue exposure for Grifulvin V given generic substitution and class competition?
Revenue exposure should be modeled as a function of:
- branded share decline curves in the presence of new generic entrants
- gross-to-net compression from rebates/chargebacks
- contract pharmacy and wholesaler channel inventory effects
- payer formulary dynamics and state-level substitution rules
Key sensitivity points
- If Orange Book patents are still active, valuation should incorporate potential delayed entry or label carve constraints.
- If no active blocking patents exist, the main forecast variable is brand share retention versus generic price erosion.
How strong is the patent estate for Grifulvin V versus typical legacy antifungal profiles?
For legacy molecules:
- enforceable IP often collapses into a small residue of product/formulation or method-of-use claims
- patent strength is commonly diluted by generic design-around capability and label carve practices
Investment conclusion on strength
- Grifulvin V’s patent strength is likely to be modest unless Orange Book shows enforceable, still-relevant patents for the exact brand NDA at the relevant dosage forms/strengths with later expiration.
What could delay generic entry or block it for Grifulvin V?
Generic entry can be delayed by:
- enforceable Orange Book patents with claim scope that covers the generic’s intended product and label
- litigation outcomes that uphold infringement or bar design-around manufacturing
- settlement agreements with agreed entry dates
- regulatory barriers such as data exclusivity for a new formulation or new dosage form (less common for legacy molecule brands)
Investment focus
- Identify whether any blocking patents are formulation-specific rather than broad composition or generic method-of-use claims that can be avoided.
Key Takeaways
- Grifulvin V is a mature griseofulvin brand whose investment fundamentals are dominated by generic substitution and class-level prescribing competition.
- The decisive diligence step for defensibility is the Orange Book status for the specific Grifulvin V NDA and the remaining enforceable patents tied to the brand’s dosage forms and label.
- Patent estate strength for legacy oral antifungals is usually limited; valuation should not assume durable exclusivity unless Orange Book lists later-dated blocking patents or ongoing litigation.
- Revenue forecasts should be sensitivity-tested around generic entry scenarios tied to Paragraph IV certifications and any settlement-imposed launch dates.
FAQs
1. What happens to Grifulvin V pricing when new generic griseofulvin entrants launch?
Expect accelerated gross-to-net erosion and branded share pressure, with channel inventory resets often driving short-term volatility followed by sustained substitution.
2. Do griseofulvin method-of-use patents stop generics from selling?
They can if claim scope and FDA labeling practices effectively restrict the generic’s intended use, but many generics can launch with label carve-outs depending on enforcement.
3. How do formulation patents affect generic bioequivalence for griseofulvin?
Formulation patents can create barriers if the generic product cannot match protected characteristics without design-around or litigation outcomes.
4. What litigation posture matters most for Hatch-Waxman cases involving Grifulvin V?
District court infringement rulings and Federal Circuit claim construction outcomes, plus settlement terms that define entry timing.
5. What FDA actions could change Grifulvin V’s competitive landscape?
Labeling updates tied to dosing or indications, approvals of new strengths, or manufacturer/quality changes that trigger bioequivalence or product comparability disputes.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
- FDA Drug Applications, Orange Book patent listing guidance and Hatch-Waxman framework resources. US Food and Drug Administration.
